Seres Therapeutics (MCRB) Q3 2024 earnings summary

Executive summary

• Achieved two major milestones: positive SER-155 Phase 1b results showing a 77% reduction in bloodstream infections in allo-HSCT patients and the sale of VOWST to Nestlé Health Science, providing significant capital and enabling debt retirement.

• Company is now focused on advancing SER-155 and other pipeline candidates, including SER-147 for chronic liver disease, and is seeking strategic partnerships to accelerate development.

• Streamlined operations post-VOWST sale, reducing headcount to approximately 100 and eliminating all outstanding debt.

• Substantial doubt exists about the ability to continue as a going concern beyond Q4 2025 without additional funding.

• Received Nasdaq notice for non-compliance with minimum bid price requirement.

Financial highlights

• Sale of VOWST generated $155M upfront, $60M prepaid milestone, $15M equity investment, and gross proceeds of $175M, with up to $275M in future milestone payments possible.

• Net loss from continuing operations was $51M for Q3 2024, compared to $41M in Q3 2023; net income from discontinued operations was $139.8M for Q3 2024, mainly due to a $146.7M gain on the VOWST sale.

• Cash and cash equivalents stood at $66.8M as of September 30, 2024, expected to fund operations into Q4 2025 with projected payments.

• R&D expenses for Q3 2024 were $16.5M, down from $25.2M in Q3 2023; G&A expenses were $12.7M, down from $19.4M.

• Operating cash outflows were $109.7M for the nine months ended September 30, 2024.

Outlook and guidance

• Expects to receive $50M in January 2025 and $25M in July 2025 from Nestlé, subject to compliance; current resources and expected payments are insufficient for long-term needs.

• Anticipates FDA feedback on Breakthrough Therapy and QIDP designations for SER-155 by year-end 2024 and plans to discuss a potential single registration study in Q1 2025.

• Exploring partnerships to maximize SER-155's potential and share development costs.

• Focused investment on advancing SER-155 and other pipeline candidates; future expenses expected to increase with clinical development.